Melittin CAS NO.20449-79-0

Melittin acts as an anti-coagulating protein by increasing the time of blood clotting in vitro. Melittin inhibits the activity of S100 calcium-binding protein B (S100B) and plays a vital role in Epilepsy treatment. Melittin retard cathepsin S-induced invasion, proliferation and angiogenesis via inhibition of the vascular endothelial growth factor A (VEGF-A) /VEGF receptor 2 (VEGFR-2)/ mitogen-activated protein kinase 1 (MEK1)/ extracellular signal-regulated kinase 1/2 (ERK1/2) pathway in human MHCC97-H cells (liver cancer cells). Melittin has therapeutic application in various inflammatory diseases such as skin inflammation, neuroinflammation, atherosclerosis, arthritis and liver inflammation. Accumulated melittin degrades phospholipid packing in the cell membrane and causes cell lysis and cell deathMelittin acts as an anti-coagulating protein by increasing the time of blood clotting in vitro. Melittin inhibits the activity of S100 calcium-binding protein B (S100B) and plays a vital role in Epilepsy treatment. Melittin retard cathepsin S-induced invasion, proliferation and angiogenesis via inhibition of the vascular endothelial growth factor A (VEGF-A) /VEGF receptor 2 (VEGFR-2)/ mitogen-activated protein kinase 1 (MEK1)/ extracellular signal-regulated kinase 1/2 (ERK1/2) pathway in human MHCC97-H cells (liver cancer cells). Melittin has therapeutic application in various inflammatory diseases such as skin inflammation, neuroinflammation, atherosclerosis, arthritis and liver inflammation. Accumulated melittin degrades phospholipid packing in the cell membrane and causes cell lysis and cell deathMelittin acts as an anti-coagulating protein by increasing the time of blood clotting in vitro. Melittin inhibits the activity of S100 calcium-binding protein B (S100B) and plays a vital role in Epilepsy treatment. Melittin retard cathepsin S-induced invasion, proliferation and angiogenesis via inhibition of the vascular endothelial growth factor A (VEGF-A) /VEGF receptor 2 (VEGFR-2)/ mitogen-activated protein kinase 1 (MEK1)/ extracellular signal-regulated kinase 1/2 (ERK1/2) pathway in human MHCC97-H cells (liver cancer cells). Melittin has therapeutic application in various inflammatory diseases such as skin inflammation, neuroinflammation, atherosclerosis, arthritis and liver inflammation. Accumulated melittin degrades phospholipid packing in the cell membrane and causes cell lysis and cell death

Melittin acts as an anti-coagulating protein by increasing the time of blood clotting in vitro. Melittin inhibits the activity of S100 calcium-binding protein B (S100B) and plays a vital role in Epilepsy treatment. Melittin retard cathepsin S-induced invasion, proliferation and angiogenesis via inhibition of the vascular endothelial growth factor A (VEGF-A) /VEGF receptor 2 (VEGFR-2)/ mitogen-activated protein kinase 1 (MEK1)/ extracellular signal-regulated kinase 1/2 (ERK1/2) pathway in human MHCC97-H cells (liver cancer cells). Melittin has therapeutic application in various inflammatory diseases such as skin inflammation, neuroinflammation, atherosclerosis, arthritis and liver inflammation. Accumulated melittin degrades phospholipid packing in the cell membrane and causes cell lysis and cell deathMelittin acts as an anti-coagulating protein by increasing the time of blood clotting in vitro. Melittin inhibits the activity of S100 calcium-binding protein B (S100B) and plays a vital role in Epilepsy treatment. Melittin retard cathepsin S-induced invasion, proliferation and angiogenesis via inhibition of the vascular endothelial growth factor A (VEGF-A) /VEGF receptor 2 (VEGFR-2)/ mitogen-activated protein kinase 1 (MEK1)/ extracellular signal-regulated kinase 1/2 (ERK1/2) pathway in human MHCC97-H cells (liver cancer cells). Melittin has therapeutic application in various inflammatory diseases such as skin inflammation, neuroinflammation, atherosclerosis, arthritis and liver inflammation. Accumulated melittin degrades phospholipid packing in the cell membrane and causes cell lysis and cell death